Zydus Cadila gets final USFDA nod for Leflunomide tablets to treat arthritis
Leflunomide tablet is used to treat rheumatoid arthritis, a condition affecting multiple small and large joints of the body.
New Delhi: Drug firm Zydus Cadila Thursday said it has received the final nod from the US health regulator to market generic Leflunomide tablets, used for the treatment of rheumatoid arthritis.
The company has received final approval from the United States Food and Drug Administration (USFDA) to market Leflunomide tablets in the strengths of 10 mg and 20 mg, Zydus Cadila said in a statement.
The tablets will be manufactured at the group's formulations manufacturing facility at Baddi in Himachal Pradesh, it added.
The tablets are a generic version of Arava tablets, Zydus Cadila said.
The drug is used to treat rheumatoid arthritis, a condition affecting multiple small and large joints of the body, it added.
The group now has 263 approvals and has so far filed over 350 abbreviated new drug applications (ANDAs) since the commencement of its filing process, it said.
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at firstname.lastname@example.org Contact no. 011-43720751 To know about our editorial team click here